Big pharma firms have between US$20b and US$40b of cash unnecessarily tied up in WC processes, equivalent to between 3.6% and 7.1% of their aggregate sales. According to EY Cash on prescription study, big pharma’s WC performance in 2012 show a further, albeit more modest, deterioration from the prio...